Gland Pharma Limited
GLAND · General/Diversified · NSE
₹2,276
Current Market Price
Fair Value (DCF)
₹1,010
Discount to FV
-55.6%
Updated 2h ago
YieldIQ Score
40/100
Piotroski F-Score
5/9
Economic Moat
Narrow
Confidence
62%
ROE
9.9%
Debt/Equity
0.03
WACC
9.5%
Market Cap
₹37,492 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
18.1%
Return on capital employed
EV / EBITDA
12.9×
Enterprise multiple
Debt / EBITDA
0.2×
Leverage vs earnings
Interest Coverage
29.4×
EBIT covers interest
Current Ratio
4.33×
Short-term liquidity
Asset Turnover
0.57×
Revenue per ₹ of assets
Revenue CAGR (3Y)
1.9%
3-year revenue growth
Revenue CAGR (5Y)
6.4%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹2,275.6
Bear case
Discount -268.0%
Base case
Discount -125.3%
Bull case
Discount -80.2%
Ratio Trends
GLAND · last 6 annual periods
ROE
9.9%
ROCE
18.1%
Operating Margin
—
Debt / Equity
0.03×
PE
27.2×
EV / EBITDA
12.9×
Historical Financials
GLAND · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹4384 Cr | ₹3592 Cr | ₹5642 Cr | ₹5617 Cr | ₹6431 Cr | +10.1% |
| EBITDA | ₹1732 Cr | ₹1208 Cr | ₹1499 Cr | ₹1483 Cr | ₹1922 Cr | +2.6% |
| EBIT | ₹1624 Cr | ₹1062 Cr | ₹1159 Cr | — | — | -8.1% |
| PAT | ₹1212 Cr | ₹781 Cr | ₹772 Cr | ₹699 Cr | ₹1027 Cr | -4.0% |
| EPS (diluted) | ₹73.64 | ₹47.43 | ₹46.89 | — | — | -10.7% |
| CFO | ₹791 Cr | ₹364 Cr | ₹997 Cr | ₹915 Cr | ₹1031 Cr | +6.9% |
| CapEx | ₹-522 Cr | ₹-223 Cr | ₹-398 Cr | ₹-394 Cr | ₹-494 Cr | — |
| FCF | ₹269 Cr | ₹141 Cr | ₹599 Cr | ₹521 Cr | ₹537 Cr | +18.9% |
| Total Assets | ₹7834 Cr | ₹8778 Cr | ₹10.7K Cr | ₹11.2K Cr | ₹12.5K Cr | +12.4% |
| Total Debt | ₹4.7 Cr | ₹4.5 Cr | ₹372 Cr | ₹314 Cr | ₹284 Cr | +178.1% |
| Shareholders' Equity | ₹7158 Cr | ₹7959 Cr | ₹8724 Cr | ₹9151 Cr | ₹10.4K Cr | +9.7% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
GLAND vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 EMCURE Emcure Pharmaceuticals Limited | -61.0% | 38 | Above Fair Value | 18.7% | — |
 JBCHEPHARM JB Chemicals & Pharmaceuticals Limited | -49.2% | 48 | Above Fair Value | 17.1% | 46.7× |
 AJANTPHARM Ajanta Pharma Limited | -57.8% | 32 | Above Fair Value | 23.3% | 33.2× |
 IPCALAB IPCA Laboratories Limited | -33.3% | 50 | Above Fair Value | 14.2% | 35.6× |
 WOCKPHARMA Wockhardt Limited | -83.8% | 20 | Data Limited | 4.3% | — |
Click a ticker to view its fair-value analysis.
Dividend History
2 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹38.00/sh
Last payout
2025-08-14
₹18.00
Peak payout
₹20.00
Trailing yield
0.79%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Gland Pharma Limited (GLAND.NS) trades at 2275.60 vs a model fair value of 1009.89, a gap of -55.6%. Piotroski F-score: 5/9. Moat label: ...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of GLAND →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for GLAND →
Compare
Head-to-head with peers
Compare GLAND side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse GLANDNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.